Smo Md GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Smo Md GmbH in Magdeburg, cardiovascular research focuses on heart and vascular disease, including high-risk patients, hypertension, and elevated cholesterol. These trials are designed to assess new ways to lower major cardiovascular events and improve long-term prevention.
- Studies in atherosclerotic cardiovascular disease, high cardiovascular risk, and related conditions
- Research on hypertension and heart, stroke, and vascular complications
- Trials evaluating treatments for LDL cholesterol, Lp(a), and broader risk reduction
Overall, this area aims to improve cardiovascular prevention and help reduce serious events such as heart attack and stroke.
Immune System Diseases
Research in immune-mediated disease at this site centers on asthma and related inflammatory conditions. The studies are mainly exploring new therapies that may better control symptoms, reduce flare-ups, and support people with more difficult-to-treat disease.
- Trials in severe asthma, eosinophilic asthma, and inadequately controlled asthma
- Investigation of treatments for COPD and airway inflammation
- Work on improving lung function and lowering exacerbation rates
This therapeutic area reflects a strong focus on respiratory inflammation and on finding more effective options for chronic airway disease.
Musculoskeletal Diseases
The musculoskeletal program includes studies in knee osteoarthritis, with attention to pain relief and everyday function. These trials are intended to evaluate whether new treatments can better ease discomfort and improve quality of life for people living with joint disease.
- Clinical research in knee osteoarthritis pain
- Evaluation of therapies aimed at reducing joint pain
- Focus on improving mobility and patient-reported outcomes
This work supports better management of degenerative joint disease through more targeted pain-control strategies.
Nutritional and Metabolic Diseases
Metabolic research at Zentrum für klinische Studien covers obesity, overweight, type 2 diabetes, and lipid disorders such as hypertriglyceridemia. The trials are testing new approaches to weight management, blood sugar control, and reduction of harmful blood fats.
- Studies in obesity and overweight, including people with type 2 diabetes
- Research on hypertriglyceridemia and lipoprotein disorders
- Trials aimed at improving body weight, glucose control, and metabolic risk
These studies are designed to support better long-term care for metabolic disease and its cardiovascular consequences.
Respiratory Tract Diseases
Respiratory trials at the site examine asthma and chronic obstructive pulmonary disease, with an emphasis on symptom control, breathing function, and prevention of worsening disease. The research includes both inhaled treatments and newer targeted therapies.
- Studies in asthma, including severe and uncontrolled asthma
- Research in COPD to reduce exacerbations and improve respiratory health
- Evaluation of therapies that may improve airway inflammation and lung function
Overall, this field is centered on finding more effective ways to manage chronic respiratory disease.
Virus Diseases
The infectious disease portfolio includes studies in influenza and herpes zoster. These trials are focused on evaluating vaccines that may improve protection, strengthen immune response, and reduce the burden of viral illness in adults.
- Vaccine research for influenza
- Studies on prevention of herpes zoster
- Assessment of immune protection and longer-term effectiveness
This area reflects ongoing efforts to improve viral disease prevention through better immunization strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB4active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Smo Md GmbH
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre randomized, double-blind, placebo-controlled, dose-finding, Phase 2 study (MARS-17) of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis. | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | Nov 2023 | Aug 2024 |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2023-08-02 | 2023-09-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
